The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC

Detalles Bibliográficos
Autor principal: Cortellini, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474225/
https://www.ncbi.nlm.nih.gov/pubmed/34589959
http://dx.doi.org/10.1016/j.jtocrr.2020.100080
_version_ 1784575165808508928
author Cortellini, Alessio
author_facet Cortellini, Alessio
author_sort Cortellini, Alessio
collection PubMed
description
format Online
Article
Text
id pubmed-8474225
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84742252021-09-28 The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC Cortellini, Alessio JTO Clin Res Rep Letter to the Editor Elsevier 2020-11-21 /pmc/articles/PMC8474225/ /pubmed/34589959 http://dx.doi.org/10.1016/j.jtocrr.2020.100080 Text en © 2020 The Author https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Cortellini, Alessio
The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
title The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
title_full The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
title_fullStr The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
title_full_unstemmed The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
title_short The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
title_sort promising link among tumor mutational burden, immune-related adverse events, and immune checkpoint inhibitors efficacy in sclc
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474225/
https://www.ncbi.nlm.nih.gov/pubmed/34589959
http://dx.doi.org/10.1016/j.jtocrr.2020.100080
work_keys_str_mv AT cortellinialessio thepromisinglinkamongtumormutationalburdenimmunerelatedadverseeventsandimmunecheckpointinhibitorsefficacyinsclc
AT cortellinialessio promisinglinkamongtumormutationalburdenimmunerelatedadverseeventsandimmunecheckpointinhibitorsefficacyinsclc

Ejemplares similares